We propose to conduct a case-control study of carcinoma in situ of the breast to be conducted in parallel with the Carolina Breast Cancer Study (CBCS). Participants will include women from the 24-county area of central and eastern North Carolina covered by the CBCS. Cases will include all women with a first diagnosis of carcinoma in situ (DCIS or LCIS) between 9/1/95 and 2/28/00 identified through the Central Cancer Registry rapid- ascertainment system developed for the CBCS. Based upon preliminary data collected during 1993, we expect 400 cases within the accrual period. Comparison subjects (controls) will consist of an equal number of women without a history of in-situ (or invasive) breast disease, frequency matched to cases based upon expected distributions by age (+/- 5 years) and race. Controls will be identified using DMV and/or HCFA records. Once a potential control has been contacted, any women who have not undergone mammography within a one year period prior to selection will be offered mammography at an institutional rate through UNC hospitals. Information on established and hypothesized risk factors for breast cancer will be obtained by personal interview using the questionnaire for the CBCS. Blood samples for extraction of germline DNA will be obtained from consenting participants, and paraffin-embedded tumor specimens and medical records will be requested for all cases. The research objectives are: (1) To identify risk factors for occurrence of DCIS and LCIS of the breast; (2) To determine whether differences in histologic appearance as well as immunohistochemical and molecular profiles of in situ lesions reflect differences in underlying etiology (i.e. exposure to specific risk factors for breast cancer); (3) To specifically evaluate the contributions of tobacco smoking and chlorinated hydrocarbon pesticides, as well as other exposures in which a study of precursor lesions is expected to have advantages over previous epidemiologic studies employing invasive breast cancer as the sole endpoint; (4) To compare cases of in-situ carcinoma in African American to Caucasian women in order to determine whether the mutational spectrum, histologic characteristics, or results of other biologic assays suggest a different (possibly more aggressive) form of breast cancer in African- American women; (5) To determine whether mutations in BRCA1, BRCA2, and other loci of inherited susceptibility represent risk factors for occurrence of in-situ carcinoma of the breast. The proposed study will benefit from utilizing the same infrastructure as the CBCS, and will involve the same group of investigators and support personnel.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-08
Application #
6203255
Study Section
Project Start
1999-08-05
Project End
2001-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Butler, Eboneé N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Echavarria, Isabel; López-Tarruella, Sara; Picornell, Antoni et al. (2018) Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 24:1845-1852
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381

Showing the most recent 10 out of 598 publications